{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:36:04Z","timestamp":1791005764205,"version":"4.1.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The presence of human immunodeficiency virus (HIV) 1 subtype A6, characterized by the L74I integrase (IN) polymorphism, is associated with confirmed virologic failure in clinical trials of long-acting cabotegravir and rilpivirine. We investigated the effect of L74I on replication capacity (RC) of recombinant viruses carrying this polymorphism in combination with various IN stand-transfer inhibitor resistance mutations. The presence of L74I conferred greater RC to recombinant viruses expressing HIV-1 A6 IN when present together with G118R, G140R, Q148H, and R263K; no significant difference in RC was observed for the Q148K or R mutants. These findings may explain, in part, the association of HIV-1 subtype A6 with virologic failure.<\/jats:p>","DOI":"10.1093\/infdis\/jiad291","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T13:24:51Z","timestamp":1690377891000},"page":"1352-1356","source":"Crossref","is-referenced-by-count":16,"title":["Effect of the L74I Polymorphism on Fitness of Cabotegravir-Resistant Variants of Human Immunodeficiency Virus 1 Subtype A6"],"prefix":"10.1093","volume":"228","author":[{"given":"Zixin","family":"Hu","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Cordwell","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hieu","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry L","family":"Jeffrey","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park , North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R","family":"Kuritzkes","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"2023111212170769100_jiad291-B1","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1097\/QAI.0000000000000469","article-title":"GSK1265744 Demonstrates robust in vitro activity against various clades of HIV-1","volume":"68","author":"Karmon","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023111212170769100_jiad291-B2","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"2023111212170769100_jiad291-B3","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"2023111212170769100_jiad291-B4","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/QAD.0000000000002883","article-title":"Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis","volume":"35","author":"Cutrell","year":"2021","journal-title":"AIDS"},{"key":"2023111212170769100_jiad291-B5","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3390\/v12080838","article-title":"Genetic features of HIV-1 integrase sub-subtype A6 predominant in Russia and predicted susceptibility to INSTIs","volume":"12","author":"Kirichenko","year":"2020","journal-title":"Viruses"},{"key":"2023111212170769100_jiad291-B6","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/QAI.0000000000002466","article-title":"Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials","volume":"85","author":"Rizzardini","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023111212170769100_jiad291-B7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/QAI.0b013e3181e9a87a","article-title":"Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness","volume":"55","author":"Hu","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023111212170769100_jiad291-B8","doi-asserted-by":"crossref","first-page":"9268","DOI":"10.1128\/JVI.00695-14","article-title":"Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors","volume":"88","author":"Hu","year":"2014","journal-title":"J Virol"},{"key":"2023111212170769100_jiad291-B9","doi-asserted-by":"crossref","first-page":"7020","DOI":"10.1128\/JVI.02747-05","article-title":"Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1","volume":"80","author":"Hu","year":"2006","journal-title":"J Virol"},{"key":"2023111212170769100_jiad291-B10","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01702-21","article-title":"Impact of integrase sequences from HIV-1 subtypes A6\/A1 on the in vitro potency of cabotegravir or rilpivirine","volume":"66","author":"Jeffrey","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023111212170769100_jiad291-B11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1126\/science.7824947","article-title":"HIV Population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy","volume":"267","author":"Coffin","year":"1995","journal-title":"Science"},{"key":"2023111212170769100_jiad291-B12","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1086\/605894","article-title":"Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C","volume":"200","author":"Invernizzi","year":"2009","journal-title":"J Infect Dis"},{"key":"2023111212170769100_jiad291-B13","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200301030-00001","article-title":"A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors","volume":"17","author":"Brenner","year":"2003","journal-title":"AIDS"},{"key":"2023111212170769100_jiad291-B14","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1128\/AAC.48.6.2159-2165.2004","article-title":"Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir","volume":"48","author":"Grossman","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2023111212170769100_jiad291-B15","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/infdis\/jiy176","article-title":"HIV-1 resistance dynamics in patients failing dolutegravir maintenance monotherapy","volume":"218","author":"Wijting","year":"2018","journal-title":"J Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad291\/51099873\/jiad291.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/10\/1352\/53307778\/jiad291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/10\/1352\/53307778\/jiad291.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T12:17:32Z","timestamp":1699791452000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/228\/10\/1352\/7232028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":15,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,7,27]]},"published-print":{"date-parts":[[2023,11,11]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad291","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,15]]},"published":{"date-parts":[[2023,7,27]]}}}